Crossmark

Investigation of KIR/HLA relationship and other clinical variables after T-cell-replete haploidentical bone marrow transplantation in patients with acute myeloid leukemia (AML)

Crossref DOI link: https://doi.org/10.1186/s12865-023-00548-1

Published Online: 2023-06-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bakhtiari, Tahereh

Ahmadvand, Mohammad

Yaghmaie, Marjan

Sadeghi, Alireza

Mousavi, Seied Asadollah

Rostami, Tahereh

Ganjalikhani-Hakemi, Mazdak
License Information

Text and Data Mining valid from 2023-06-20

Version of Record valid from 2023-06-20
More Information

Article History

Received: 5 November 2022

Accepted: 7 June 2023

First Online: 20 June 2023

Declarations

:

: All experimental protocols were approved by the ethical standards of the Ethic Committee of Research Institute for Oncology, Hematology and Cell Therapy of Tehran University of Medical Sciences (IR.MUI.REC.1400.036), and informed consent was obtained from all individual participants included in the study. In the case of minors, informed consent was obtained from the parents or legal guardians of any participant under the age of 16. All methods were carried out in accordance with relevant guidelines and regulations.

: Not applicable.

: The authors have no relevant conflicts of interest.

Document is current

Any future updates will be listed below